Geron Corporation $GERN Stock: Edmond DE Rothschild Holding S.A. Reduces Stake

Edmond DE Rothschild Holding S.A. trimmed its holdings in Geron Corporation (NASDAQ:GERN – Free Report) by 48.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,200,000 shares of the biopharmaceutical company’s stock after selling 1,130,000 shares during the quarter. Edmond DE Rothschild Holding S.A. owned 0.19% of Geron worth $1,476,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of GERN. BlackRock Inc. bought a new position in shares of Geron during the second quarter valued at $62,868,000. Eversept Partners LP grew its stake in shares of Geron by 6.7% during the first quarter. Eversept Partners LP now owns 18,834,883 shares of the biopharmaceutical company’s stock worth $28,064,000 after purchasing an additional 1,174,900 shares during the period. Nantahala Capital Management LLC bought a new stake in Geron in the second quarter valued at approximately $15,648,000. Candriam S.C.A. raised its position in shares of Geron by 42.8% during the third quarter. Candriam S.C.A. now owns 7,982,968 shares of the biopharmaceutical company’s stock worth $9,855,000 after purchasing an additional 2,393,786 shares during the period. Finally, Pale Fire Capital SE lifted its stake in Geron by 8.6% in the second quarter. Pale Fire Capital SE now owns 5,307,204 shares of the biopharmaceutical company’s stock valued at $6,793,000 after buying an additional 418,900 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Price Performance

Geron stock opened at $0.87 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 4.61 and a current ratio of 6.31. The stock has a market capitalization of $560.49 million, a P/E ratio of -10.88 and a beta of 0.62. Geron Corporation has a 52 week low of $0.84 and a 52 week high of $2.01. The stock has a fifty day moving average of $1.13 and a 200-day moving average of $1.39.

Analysts Set New Price Targets

GERN has been the topic of a number of recent research reports. Needham & Company LLC lowered their price objective on shares of Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Finally, Wedbush decreased their price target on shares of Geron to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 28th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Check Out Our Latest Stock Report on GERN

Geron Company Profile

(Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

See Also

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Corporation (NASDAQ:GERN – Free Report).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.